XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information - Summary of Information by Business Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Revenues from External Customers $ 383,135 $ 377,128 $ 1,072,927 $ 1,309,779
Equity in the Net Income (Loss) of Investees Accounted for by the Equity Method (2,493) 991 2,938 14,599
Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Revenues from External Customers 383,135 377,128 1,072,927 1,309,779
Equity in the Net Income (Loss) of Investees Accounted for by the Equity Method (2,494) (422) (5,650) (689)
Adjusted EBITDA 250,183 198,960 705,764 660,444
Segment Expenditures     597,056 299,513
Operating Segments [Member] | Upstream [Member]        
Segment Reporting Information [Line Items]        
Revenues from External Customers 383,135 377,128 1,072,927 1,309,779
Equity in the Net Income (Loss) of Investees Accounted for by the Equity Method 118 75 373 5
Adjusted EBITDA 255,228 199,675 719,326 669,103
Segment Expenditures     559,873 297,486
Operating Segments [Member] | All Other [Member]        
Segment Reporting Information [Line Items]        
Revenues from External Customers [1] 0 0 0 0
Equity in the Net Income (Loss) of Investees Accounted for by the Equity Method [1] (2,612) (497) (6,023) (694)
Adjusted EBITDA [1] $ (5,045) $ (715) (13,562) (8,659)
Segment Expenditures [1]     $ 37,183 $ 2,027
[1] The CCS Segment is included in the “All Other” category. The CCS Segment is an emerging business in the start-up phase of operations and the business that does not currently generate any revenues. The CCS Segment’s business activities are conducted through both wholly owned subsidiaries and equity method investments with industry partners. Equity method investments is a business strategy that enables us to achieve favorable economies of scale relative to the level of investment and business risk assumed.